Market news

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three...

Haleon plc (NYSE:HLN) is trying to win the US consumer-health market one shelf at a time. The Sensodyne and Advil owner has secured more prominent positions at Walmart Inc. (NYSE:WMT), Target Corporation (NYSE:TGT), and other major retailers by offering improved commercial terms, including lower prices, stronger promotions, new products, and exclusivity. READ ALSO: Keurig Dr […]

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include...

Haleon plc (NYSE:HLN) is finding a new growth opportunity in the expanding U.S. population using GLP-1 weight-loss drugs such as Wegovy and Zepbound. According to Reuters, the company has been placing products that can address GLP-1-related side effects in both its normal store locations and dedicated GLP-1 sections at CVS. That strategy has produced an […]

Haleon said the site was "no longer a viable option" following a strategic review in 2024.

Haleon boosts Advil/Tums sales as GLP-1 users manage side effects. Read more here.

Advil maker Haleon is capitalizing on the GLP-1 boom, boosting sales of products that combat weight loss drugs side effects with strategic store placement.

Shelf placement is becoming an increasingly important competitive weapon at Walmart Inc. (NYSE:WMT) and Target Corporation (NYSE:TGT). Haleon, the company behind Sensodyne, Advil, and Centrum, has negotiated more prominent positions at the two retailers by offering lower prices, stronger promotions, exclusive products, and other improved commercial terms. The strategy appears to be benefiting Haleon, whose […]

The 1950s site will be knocked down and replaced with three smaller units if the plan is approved.

Haleon (HLN) has negotiated better shelf placement at Walmart (WMT) and Target (TGT), Reuters report

Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this...

Detailed price information for Haleon Plc (HLN-N) from The Globe and Mail including charting and trades.

Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "TenderOffer").

Detailed price information for Haleon Plc (HLN-N) from The Globe and Mail including charting and trades.

Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrued Interest (each as defined below) (the "Tender Offer").

Haleon, a leading consumer health company focused on better everyday health, and the A*STAR Institute for Human Development and Potential (A*STAR IHDP) today announced the launch of a new clinical study known as the Impact of Multivitamin and Mineral Supplementation on Metabolic Health in Midlife Women (ISMOS). The study on Centrum will further establish the role of multivitamin and mineral (MVM) supplementation on metabolic health among middle-aged Asian women, who are often under-represented i

Daniela Cavinatto Daniela Cavinatto joins Haleon as General Manager, Canada MISSISSAUGA, Ontario, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Haleon, a leading global consumer company, today announced the appointment of Daniela Cavinatto as General Manager, Canada. Daniela joins Haleon with more than 25 years of international leadership experience and a strong track record of driving business growth, leading transformation and building high-performing teams across complex consumer markets. In her role, Da

Detailed price information for Haleon Plc (HLN-N) from The Globe and Mail including charting and trades.

Haleon (NYSE:HLN) said its second-quarter organic sales growth accelerated to 3.1% from 2.2% in the first quarter, supported by improved execution in North America, continued growth in emerging markets and a stronger contribution from pain relief and oral health products. Chief Executive Officer Br

July 30 (Reuters) - Sluggish European demand and weak respiratory sales raised doubts on Thursday about whether Haleon can ‌meet its sales targets, sending shares in the consumer health company lower despite ‌better-than-expected first-half profit. The British maker of Theraflu and Flonase cold medicines and Sensodyne toothpaste reported first-half organic ​revenue growth of 2.

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 2.9% to 368.7p after the consumer healthcare group reported improving second-quarter sales but left its full-year guidance unchanged. Organic revenue increased 3.1% in the second quarter, split between 1.7% from pricing and 1.4% from volumes and...

Haleon plc (LSE:HLN) has released its half-year 2026 results, publishing the full report through the London Stock Exchange and on its corporate website. The update provides investors with the group’s latest financial performance while reaffirming its commitment to maintaining transparent communication with shareholders and the market.